Human papillomavirus infection in women with and without cervical cancer in Ibadan, Nigeria

Infectious Agents and Cancer

Volumn 5, Issue 1, 2010, Pages

  Okolo, Clement ^a   Franceschi, Silvia ^b   Adewole, Isaac ^a   Thomas, Jaiye O ^a   Follen, Michele ^c   Snijders, Peter J F ^d   Meijer, Chris J L M ^d   Clifford, Gary M ^b  

^a UNIVERSITY OF IBADAN   (Nigeria)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INVASION; CARCINOGENICITY; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 35; MAJOR CLINICAL STUDY; NIGERIA; PAPILLOMAVIRUS INFECTION; POPULATION; PREVALENCE; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

EID: 78649538518     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-5-24     Document Type: Article

References (20)

1. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. J Ferlay HR Shin F Bray D Forman C Mathers DM Parkin, IARC CancerBase No. 10 [Internet] Lyon, France, International Agency for Research on Cancer 2010 http://globocan.iarc.fr
2. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. GM Clifford S Gallus R Herrero N Munoz PJ Snijders S Vaccarella,, et al. Lancet 2005 366 991 998 10.1016/S0140-6736(05)67069-9 16168781
3. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. JO Thomas R Herrero AA Omigbodun K Ojemakinde IO Ajayi A Fawole,, et al. Br J Cancer 2004 90 638 645 10.1038/sj.bjc.6601515 14760378 (Pubitemid 38297204)
4. Human papillomavirus genotypes in rural Mozambique. X Castellsagué C Menendez MP Loscertales JR Kornegay F dos Santos FX Gomez-Olive,, et al. Lancet 2001 358 1429 1430 11705494
5. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. PE Castle D Solomon M Schiffman CM Wheeler, J Natl Cancer Inst 2005 97 1066 1071 10.1093/jnci/dji186 16030304
6. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. MJ Khan PE Castle AT Lorincz S Wacholder M Sherman DR Scott,, et al. J Natl Cancer Inst 2005 97 1072 1079 10.1093/jnci/dji187 16030305
7. HPV infection in women with and without cervical cancer in Conakry, Guinea. N Keita GM Clifford M Koulibaly K Douno I Kabba M Haba,, et al. Br J Cancer 2009 101 202 208 10.1038/sj.bjc.6605140 19536089
8. Distribution of human papillomavirus in a family planning population in Nairobi, Kenya. H De Vuyst S Steyaert L Van Renterghem P Claeys L Muchiri S Sitati,, et al. Sex Transm Dis 2003 30 137 142 10.1097/00007435-200302000-00009 12567172
9. Comparison of non-invasive sampling methods for detection of HPV in rural African women. N Lack B West D Jeffries G Ekpo L Morison WP Soutter,, et al. Sex Transm Infect 2005 81 239 241 10.1136/sti.2004.010413 15923294
10. Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology. SR Wall CF Scherf L Morison KW Hart B West G Ekpo,, et al. Br J Cancer 2005 93 1068 1076 10.1038/sj.bjc.6602736 16106268
11. Human papillomavirus in a rural community in Zimbabwe: the impact of HIV co-infection on HPV genotype distribution. MF Baay EF Kjetland PD Ndhlovu V Deschoolmeester T Mduluza E Gomo,, et al. J Med Virol 2004 73 481 485 10.1002/jmv.20115 15170646
12. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. KS Cuschieri HA Cubie MW Whitley AL Seagar MJ Arends C Moore,, et al. J Clin Pathol 2004 57 68 72 10.1136/jcp.57.1.68 14693839
13. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? SK Kjaer AJ van den Brule JE Bock PA Poll G Engholm ME Sherman,, et al. Cancer Epidemiol Biomarkers Prev 1997 6 799 805 9332762
14. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. N Li S Franceschi R Howell-Jones PJ Snijders GM Clifford, Int J Cancer 2010 20473886
15. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. S de Sanjosé WG Quint L Alemany DT Geraets JE Klaustermeier B Lloveras,, et al. Lancet Oncol 2010 11 1048 1056 20952254
16. Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: burden and potential for prevention. X Castellsagué J Klaustermeier C Carrilho G Albero J Sacarlal W Quint,, et al. Int J Cancer 2008 122 1901 1904 18076064
17. Long-term Absolute Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse Following Human Papillomavirus Infection: Role of Persistence. SK Kjaer K Frederiksen C Munk T Iftner, J Natl Cancer Inst 2010 102 1 11 10.1093/jnci/djp493
18. A review of human carcinogens - Part B: biological agents. V Bouvard R Baan K Straif Y Grosse B Secretan F El Ghissassi,, et al. Lancet Oncol 2009 10 321 322 10.1016/S1470-2045(09)70096-8 19350698
19. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. J Paavonen P Naud J Salmeron CM Wheeler SN Chow D Apter,, et al. Lancet 2009 374 301 314 10.1016/S0140-6736(09)61248-4 19586656
20. The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years. CM Wheeler SK Kjaer K Sigurdsson OE Iversen M Hernandez-Avila G Perez,, et al. J Infect Dis 2009 199 936 944 10.1086/597309 19236277